Antibody Drug Conjugates

Antibody Drug Conjugates (ADC’S) represent a ground-breaking class of therapeutics that combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs, resulting in highly targeted and effective treatments for various diseases.

ADCs are designed to selectively deliver cytotoxic drugs to specific cells or tissues by utilizing monoclonal antibodies as carriers. The antibodies recognize and bind to specific antigens expressed on the surface of target cells, allowing for precise localization of the therapeutic payload. This targeted delivery approach minimizes the distribution of the cytotoxic drug in healthy tissues thus enhancing the therapeutic window, maximizing efficacy while reducing systemic toxicity. Conjugation of payloads other than cytotoxic drugs is currently also investigated. Diverse molecules such as toxins, antibiotics, immune modulatory drugs and oligonucleotides have already been evaluated in an ADC format.

Evotec's extensive experience in antibody discovery and engineering, combined with their proficiency in medicinal chemistry and linker technologies, positions them at the forefront of ADC development. Our expert usage of the Ab/linker/payload/bioconjugation toolbox available, allows for the rational optimization of ADCs with improved stability, enhanced drug release kinetics, and increased selectivity.

Accelerating ADC Success with Innovative Infrastructure

By leveraging our state-of-the-art infrastructure and cutting-edge technologies, we are able to conduct comprehensive preclinical evaluations to assess the safety, efficacy, and pharmacokinetic properties of ADC candidates. These evaluations include in vitro and in vivo studies, as well as rigorous toxicology assessments, ensuring the development of high-quality ADCs with the potential for clinical success.

Evotec's collaborative partnerships with pharmaceutical and biotechnology companies, as well as academic institutions, further enhance their ADC discovery and development capabilities. By leveraging our diverse expertise, we can engage in multidisciplinary collaborations that facilitate the identification and optimization of novel ADC candidates, ultimately driving the development of next-generation therapies.

Christophe Boldron

Christophe Boldron

VP Head of Molecular Architects

Logo Evotec white
Evotec has the right technologies & disease understanding to meet our partners' evolving needs: a comprehensive disease knowledge at the molecular level, cutting-edge technologies & platforms to translate this expertise into effective precision medicines.